Report Detail
Global (United States, European Union and China) Dyslipidemia Drugs Market Research Report 2019-2025
- RnM3703907 |
- 28 August, 2019 |
- Global |
- 127 Pages |
- QYResearch |
- Pharma & Healthcare
Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.
The increasing risk of cardiovascular disease (CVDs) is the primary driver for the market’s growth. Elevated cholesterol levels account for nearly one-third of the total ischemic heart diseases and persist as a substantial cause of ischemic heart diseases and strokes in emerging countries such as India and China. Thus, the cardiovascular risk management guidelines set by authorities such as the American College of Cardiology and American Heart Association acknowledge the decreasing the blood cholesterol as a prime factor in cutting down on the cardiovascular risks. This, in turn, drives the cholesterol maintaining drugs to avoid CVDs risk and boosting the sales of the drugs market.
With the presence of numerous small and larger vendors, the global dyslipidemia drugs market is largely competitive. Competition is observed from the regional players globally, and there are numerous new manufacturers entering the market. Moreover, companies like Amgen, HanAll BioPharma, Kowa Pharmaceuticals, CJ HealthCare, Catabasis Pharmaceuticals, JW Pharmaceuticals, and Esperion Pharmaceuticals are expected to enter the market over the next four years.
In 2019, the market size of Dyslipidemia Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Dyslipidemia Drugs.
This report studies the global market size of Dyslipidemia Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Dyslipidemia Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
AstraZeneca
Merck
Pfizer
Sanofi
Alnylam Pharmaceuticals
Amarin Corporation
Amgen
Bristol-Myers Squibb
Catabasis Pharmaceuticals
Cerenis
Cipla
CJ HealthCare
CKD Bio
Daewoong Pharmaceutical
Daiichi Sankyo
Eli Lilly
Esperion Therapeutics
GlaxoSmithKline
JW Pharmaceuticals
Kadmon Pharmaceuticals
Lupin Pharmaceuticals
Market Segment by Product Type
Statins
Cholesterol absorption inhibitors
Dyslipidemia injectable
Market Segment by Application
Hospitals and Clinics
Medical Laboratories
Drug Stores
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Dyslipidemia Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Dyslipidemia Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Dyslipidemia Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Dyslipidemia Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Statins
- 1.3.3 Cholesterol absorption inhibitors
- 1.3.4 Dyslipidemia injectable
- 1.4 Market Segment by Application
- 1.4.1 Global Dyslipidemia Drugs Market Share by Application (2019-2025)
- 1.4.2 Hospitals and Clinics
- 1.4.3 Medical Laboratories
- 1.4.4 Drug Stores
- 1.4.5 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Dyslipidemia Drugs Market Size
- 2.1.1 Global Dyslipidemia Drugs Revenue 2014-2025
- 2.1.2 Global Dyslipidemia Drugs Sales 2014-2025
- 2.2 Dyslipidemia Drugs Growth Rate by Regions
- 2.2.1 Global Dyslipidemia Drugs Sales by Regions 2014-2019
- 2.2.2 Global Dyslipidemia Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Dyslipidemia Drugs Sales by Manufacturers
- 3.1.1 Dyslipidemia Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Dyslipidemia Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Dyslipidemia Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Dyslipidemia Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Dyslipidemia Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Dyslipidemia Drugs Price by Manufacturers
- 3.4 Key Manufacturers Dyslipidemia Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Dyslipidemia Drugs Market
- 3.6 Key Manufacturers Dyslipidemia Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Statins Sales and Revenue (2014-2019)
- 4.1.2 Cholesterol absorption inhibitors Sales and Revenue (2014-2019)
- 4.1.3 Dyslipidemia injectable Sales and Revenue (2014-2019)
- 4.2 Global Dyslipidemia Drugs Sales Market Share by Type
- 4.3 Global Dyslipidemia Drugs Revenue Market Share by Type
- 4.4 Dyslipidemia Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Dyslipidemia Drugs Sales by Application
6 United States
- 6.1 United States Dyslipidemia Drugs Breakdown Data by Company
- 6.2 United States Dyslipidemia Drugs Breakdown Data by Type
- 6.3 United States Dyslipidemia Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Dyslipidemia Drugs Breakdown Data by Company
- 7.2 European Union Dyslipidemia Drugs Breakdown Data by Type
- 7.3 European Union Dyslipidemia Drugs Breakdown Data by Application
8 China
- 8.1 China Dyslipidemia Drugs Breakdown Data by Company
- 8.2 China Dyslipidemia Drugs Breakdown Data by Type
- 8.3 China Dyslipidemia Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Dyslipidemia Drugs Breakdown Data by Company
- 9.2 Rest of World Dyslipidemia Drugs Breakdown Data by Type
- 9.3 Rest of World Dyslipidemia Drugs Breakdown Data by Application
- 9.4 Rest of World Dyslipidemia Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Dyslipidemia Drugs Sales by Countries
- 9.4.2 Rest of World Dyslipidemia Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 AstraZeneca
- 10.1.1 AstraZeneca Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.1.4 Dyslipidemia Drugs Product Introduction
- 10.1.5 AstraZeneca Recent Development
- 10.2 Merck
- 10.2.1 Merck Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.2.4 Dyslipidemia Drugs Product Introduction
- 10.2.5 Merck Recent Development
- 10.3 Pfizer
- 10.3.1 Pfizer Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.3.4 Dyslipidemia Drugs Product Introduction
- 10.3.5 Pfizer Recent Development
- 10.4 Sanofi
- 10.4.1 Sanofi Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.4.4 Dyslipidemia Drugs Product Introduction
- 10.4.5 Sanofi Recent Development
- 10.5 Alnylam Pharmaceuticals
- 10.5.1 Alnylam Pharmaceuticals Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.5.4 Dyslipidemia Drugs Product Introduction
- 10.5.5 Alnylam Pharmaceuticals Recent Development
- 10.6 Amarin Corporation
- 10.6.1 Amarin Corporation Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.6.4 Dyslipidemia Drugs Product Introduction
- 10.6.5 Amarin Corporation Recent Development
- 10.7 Amgen
- 10.7.1 Amgen Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.7.4 Dyslipidemia Drugs Product Introduction
- 10.7.5 Amgen Recent Development
- 10.8 Bristol-Myers Squibb
- 10.8.1 Bristol-Myers Squibb Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.8.4 Dyslipidemia Drugs Product Introduction
- 10.8.5 Bristol-Myers Squibb Recent Development
- 10.9 Catabasis Pharmaceuticals
- 10.9.1 Catabasis Pharmaceuticals Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.9.4 Dyslipidemia Drugs Product Introduction
- 10.9.5 Catabasis Pharmaceuticals Recent Development
- 10.10 Cerenis
- 10.10.1 Cerenis Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Dyslipidemia Drugs
- 10.10.4 Dyslipidemia Drugs Product Introduction
- 10.10.5 Cerenis Recent Development
- 10.11 Cipla
- 10.12 CJ HealthCare
- 10.13 CKD Bio
- 10.14 Daewoong Pharmaceutical
- 10.15 Daiichi Sankyo
- 10.16 Eli Lilly
- 10.17 Esperion Therapeutics
- 10.18 GlaxoSmithKline
- 10.19 JW Pharmaceuticals
- 10.20 Kadmon Pharmaceuticals
- 10.21 Lupin Pharmaceuticals
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Dyslipidemia Drugs Sales Channels
- 11.2.2 Dyslipidemia Drugs Distributors
- 11.3 Dyslipidemia Drugs Customers
12 Market Forecast
- 12.1 Global Dyslipidemia Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Dyslipidemia Drugs Sales Forecast by Type
- 12.3 Global Dyslipidemia Drugs Sales Forecast by Application
- 12.4 Dyslipidemia Drugs Forecast by Regions
- 12.4.1 Global Dyslipidemia Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Dyslipidemia Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Dyslipidemia Drugs. Industry analysis & Market Report on Dyslipidemia Drugs is a syndicated market report, published as Global (United States, European Union and China) Dyslipidemia Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Dyslipidemia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
